Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, Michael [1 ]
Butler, J. [2 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Abdin, A. [1 ]
Mahfoud, F. [1 ]
Brueckmann, M. [6 ]
Saloustros, I. [6 ]
Schueler, E. [7 ]
Ponikowski, P. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Anker, S. D. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med 3, Cardiol Angiol & Intens Care Med, Homburg, Germany
[2] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
[3] Natl & Kapodistrian Univ Athens, Med Sch, Dept Med, Athens, Greece
[4] Univ Lorraine, INSERM, Ctr Invest Clin Plurithemat, CICP 1433, Nancy, France
[5] London Sch Hyg & Trop Med, London, England
[6] Boehringer Ingelheim Int, Ingelheim, Germany
[7] Mainanalyt GmbH, Sulzbach, Germany
[8] Wroclaw Med Univ, Wroclaw, Poland
[9] Univ Hosp Wurzburg, Wurzburg, Germany
[10] Baylor Univ, Med Ctr, Dallas, TX USA
[11] German Ctr Cardiovasc Res DZHK, Berlin Inst Hlth Ctr Regenerat Therapies, Dept Cardiol BCRT, Partner Site Berlin, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [1] Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Anker, Stefan
    Mahfoud, Felix
    Lauder, Lucas
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Saloustros, Ilias
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Butler, Javed
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (05) : 396 - 407
  • [2] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Gollop, N. D.
    Iwata, T.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 131 - 132
  • [3] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Krawczyk, Marcin
    Mahfoud, Felix
    Haring, Bernhard
    Filippatos, Gerasimos
    Ferreira, Joao Pedro J.
    Pocock, Stuart
    Brueckmann, Martina
    Ofstad, Anne Pernille
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Packer, Milton D.
    Anker, Stefan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
  • [4] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [5] Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial
    Boehm, M.
    Anker, S. D.
    Mahfoud, F.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Brueckmann, M.
    Linetzky, B.
    Schueler, E.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 983 - 983
  • [6] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease
    Wanner, Christoph
    [J]. INTERNIST, 2022, 63 (SUPPL 3): : 349 - 349
  • [7] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    [J]. CIRCULATION, 2022, 146
  • [8] Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Butler, Javed
    Filippatos, Gerasimos
    Siddiqi, Tariq Jamal
    Brueckmann, Martina
    Bohm, Michael
    Chopra, Vijay K.
    Ferreira, Joao Pedro
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Shah, Sanjiv J.
    Senni, Michele
    Vedin, Ola
    Verma, Subodh
    Peil, Barbara
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    [J]. CIRCULATION, 2022, 145 (03) : 184 - 193
  • [9] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Huynh, Karina
    [J]. NATURE REVIEWS CARDIOLOGY, 2021, 18 (11) : 737 - 737
  • [10] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
12345